Markets:

Overview

News

Currencies

International

Treasuries

Apellis Pharmaceuticals, Inc. - Common Stock (NQ:APLS)

23.49 +0.93 (+4.12%)

Streaming Delayed Price Updated: 4:00 PM EST, Feb 6, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

Headline News about Apellis Pharmaceuticals, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9

...

12 13 Next >

Wedbush Just Raised its Price Target on These 7 Stocks: August 12, 2024 ↗

August 13, 2024

New Wedbush price targets have been issued for each of the following seven stocks, including a few that may come as a surprise to some.

Via InvestorPlace

Apellis Pharmaceuticals' Pegcetacoplan Meets Primary Goal In Late-Stage Study In Patients With Rare Kidney Diseases ↗

August 08, 2024

Swedish Orphan Biovitrum and Apellis Pharmaceuticals released topline results from the Phase 3 VALIANT study of pegcetacoplan for C3 glomerulopathy and IC-MPGN. The study met primary and secondary...

Via Benzinga

Critical Insights From Apellis Pharmaceuticals Analyst Ratings: What You Need To Know ↗

August 02, 2024

Via Benzinga

Peeling Back The Layers: Exploring Apellis Pharmaceuticals Through Analyst Insights ↗

July 17, 2024

Via Benzinga

What Analysts Are Saying About Apellis Pharmaceuticals Stock ↗

June 28, 2024

Via Benzinga

Nike, Accolade And Other Big Stocks Moving Lower In Friday's Pre-Market Session ↗

June 28, 2024

Via Benzinga

Expert Outlook: Apellis Pharmaceuticals Through The Eyes Of 15 Analysts ↗

May 28, 2024

Via Benzinga

In-Depth Examination Of 14 Analyst Recommendations For Apellis Pharmaceuticals ↗

May 08, 2024

Via Benzinga

APLS Stock Earnings: Apellis Pharmaceuticals Misses EPS, Beats Revenue for Q1 2024 ↗

May 07, 2024

APLS stock results show that Apellis Pharmaceuticals missed analyst estimates for earnings per share but beat on revenue for the first quarter of 2024.

Via InvestorPlace

Expert Ratings For Apellis Pharmaceuticals ↗

April 15, 2024

Via Benzinga

If You Invested $1000 In This Stock 5 Years Ago, You Would Have $3,000 Today ↗

April 10, 2024

Via Benzinga

$1000 Invested In This Stock 5 Years Ago Would Be Worth $3,000 Today ↗

March 29, 2024

Via Benzinga

Decoding 15 Analyst Evaluations For Apellis Pharmaceuticals ↗

March 27, 2024

Via Benzinga

Peering Into Apellis Pharmaceuticals's Recent Short Interest ↗

March 15, 2024

Via Benzinga

Deep Dive Into Apellis Pharmaceuticals Stock: Analyst Perspectives (18 Ratings) ↗

February 28, 2024

Via Benzinga

Earnings Scheduled For February 27, 2024 ↗

February 27, 2024

Companies Reporting Before The Bell • Gaotu Techedu (NYSE:GOTU) is expected to report quarterly loss at $0.07 per share on revenue of $100.49 million.

Via Benzinga

Here's How Much You Would Have Made Owning Apellis Pharmaceuticals Stock In The Last 5 Years ↗

February 22, 2024

Via Benzinga

$1000 Invested In Apellis Pharmaceuticals 5 Years Ago Would Be Worth This Much Today ↗

February 05, 2024

Via Benzinga

ICU Medical To Rally Around 28%? Here Are 10 Top Analyst Forecasts For Wednesday ↗

February 28, 2024

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page.

Via Benzinga

Pinterest To Rally Over 20%? Here Are 10 Top Analyst Forecasts For Monday ↗

February 05, 2024

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page.

Via Benzinga

Critical Insights From Apellis Pharmaceuticals Analyst Ratings: What You Need To Know ↗

January 30, 2024

Via Benzinga

Netflix To Rally Around 18%? Here Are 10 Top Analyst Forecasts For Wednesday ↗

January 24, 2024

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page.

Via Benzinga

Apellis Pharmaceuticals Stock: A Deep Dive Into Analyst Perspectives (12 Ratings) ↗

January 09, 2024

Via Benzinga

Netflix To Rally Over 13%? Here Are 10 Top Analyst Forecasts For Wednesday ↗

January 17, 2024

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page.

Via Benzinga

10 Health Care Stocks With Whale Alerts In Today's Session ↗

January 15, 2024

Via Benzinga

10 Health Care Stocks With Whale Alerts In Today's Session ↗

December 25, 2023

Via Benzinga

Karuna Therapeutics Jumps Following Takeover By Bristol Myers, Joins Rocket Lab USA, Altair Engineering And Other Big Stocks Moving Higher On Friday ↗

December 22, 2023

U.S. stocks traded higher, with the Dow Jones index gaining around 50 points on Friday. Shares of Karuna Therapeutics, Inc. (NASDAQ: KRTX) rose sharply during Friday’s session following acquisition...

Via Benzinga

Topics Stocks

Why Is Complement-Mediated Focused Annexon Stock Trading Higher Today? ↗

December 21, 2023

On Wednesday, Annexon Inc (NASDAQ: ANNX) reported results from the Phase 1 single ascending dose (SAD) and multiple ascending dose (MAD) healthy volunteer study of ANX1502 that targets the active form...

Via Benzinga

Micron Technology To Rally Over 15%? Here Are 10 Top Analyst Forecasts For Friday ↗

December 15, 2023

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page.

Via Benzinga

US Stocks Eye 7-Day Winning Streak As Mortgage Rates Fall Below 7%, Yields Tumble: What's Driving Markets Thursday? ↗

December 14, 2023

It’s shaping up to be a positive Thursday on Wall Street, with risk sentiment remaining robust after the Federal Reserve effectively opened the door to rate cuts in 2024.

Via Benzinga

Topics Economy

< Previous 1 2 3 4 5 6 7 8 9

...

12 13 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Apellis Pharmaceuticals, Inc. - Common Stock (NQ:APLS)

Headline News about Apellis Pharmaceuticals, Inc. - Common Stock

Starting at $3.75/week.

Subscribe Today